GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Market Cap

Neurocrine Biosciences (Neurocrine Biosciences) Market Cap : $13,936 Mil (As of May. 14, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Neurocrine Biosciences's share price for the quarter that ended in Mar. 2024 was $137.92. Neurocrine Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 101 Mil. Therefore, Neurocrine Biosciences's market cap for the quarter that ended in Mar. 2024 was $13,872 Mil.

Neurocrine Biosciences's quarterly market cap increased from Sep. 2023 ($11,048 Mil) to Dec. 2023 ($13,005 Mil) and increased from Dec. 2023 ($13,005 Mil) to Mar. 2024 ($13,872 Mil).

Neurocrine Biosciences's annual market cap increased from Dec. 2021 ($8,083 Mil) to Dec. 2022 ($11,526 Mil) and increased from Dec. 2022 ($11,526 Mil) to Dec. 2023 ($13,005 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neurocrine Biosciences's Enterprise Value for Today is $13,003 Mil.


Neurocrine Biosciences Market Cap Historical Data

The historical data trend for Neurocrine Biosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Market Cap Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,918.32 8,961.98 8,082.63 11,525.96 13,004.71

Neurocrine Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,868.95 9,203.68 11,047.50 13,004.71 13,871.99

Competitive Comparison of Neurocrine Biosciences's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Market Cap falls into.



Neurocrine Biosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Neurocrine Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$131.76*98.7
=$13,005

Neurocrine Biosciences's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$137.92*100.58
=$13,872

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences  (NAS:NBIX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Neurocrine Biosciences Market Cap Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080